Skip to main content
Aller à la page d’accueil de la Commission européenne (s’ouvre dans une nouvelle fenêtre)
français fr
CORDIS - Résultats de la recherche de l’UE
CORDIS

X-chromosome role in SEx-dependent Lymphoma Evolution and Clonal Trajectories

Objectif

Despite recent advances, we still lack a coherent framework explaining how genetic lesions, aberrant cell fate decisions and host factors intersect to drive immunological neoplasms (lymphoma). We have uncovered an entirely new dimension: gender bias as a fundamental driver of lymphoma evolution. Our data show that a newly discovered type of lymphoma called BN2-DLBCL, defined by SPEN and NOTCH2 truncations, is specifically highly aggressive in women and rooted in the biology of aged/autoimmune B cells (AiBCs); cells classically linked to autoimmunity. This suggests a central role for female gender effects where immune dysfunction, chronic inflammation, and failed X-chromosome inactivation (XCI) converge. We hypothesize that SPEN loss destabilizes XCI, unleashing bi-allelic expression of X-encoded TLR7/IRAK1 and hyperactive inflammatory signaling; NOTCH2 mutations reroute these signals into AiBC fate, creating lymphoma precursors that expand clonally, exhaust T cells, and reshape immune microenvironments. The result is a uniquely female-biased malignant trajectory, overturning conventional lymphoma paradigms. With X-SeLECT (X-chromosome role in SEx-dependent Lymphoma Evolution and Clonal Trajectories) we will systematically dissect this biology. Using single-cell multi-omics, spatial proteogenomics, real-time dynamics (3-photon microscopy), and lineage tracing, we will reconstruct the stepwise clonal evolution of AiBCs into BN2-DLBCL and define the gender-specific immune circuits that sustain them. Finally, we will exploit these insights to uncover sex-specific vulnerabilities, testing how TLR/IRAK blockade, statins, and immune checkpoint synergy can dismantle these malignant networks. This project will deliver a paradigm shift: establishing AiBCs as the first bona fide lymphoma-initiating and repopulating cells, demonstrating that gender and X-linked immunity are central to cancer biology, and charting the way toward precision, sex-informed therapies in lymphoma.

Champ scientifique (EuroSciVoc)

Ce projet n'a pas encore été classé par EuroSciVoc.
Proposez les domaines scientifiques qui vous semblent les plus pertinents et aidez-nous à améliorer notre service de classification.

Mots‑clés

Programme(s)

Thème(s)

Régime de financement

HORIZON-ERC - HORIZON ERC Grants

Voir tous les projets financés dans le cadre de ce programme de financement

Appel à propositions

(s’ouvre dans une nouvelle fenêtre) ERC-2025-ADG

Voir tous les projets financés au titre de cet appel

Institution d’accueil

FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS
Contribution nette de l'UE
€ 3 499 123,75
Coût total
Aucune donnée

Bénéficiaires (1)